Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

By WebmasterDecember 7, 2020November 1st, 2024No Comments

Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with
Major Depressive Disorder

Previous PostEnvara Health Named Winner of Rabobank's FoodBytes! Pitch 2020 Competition
Next PostVenatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC